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Self/non-self discrimination is a fundamental requirement of life. Endogenous peptides presented by
major histocompatibility complex class I (MHC I) molecules represent the essence of self for CD8 T
lymphocytes. These MHC I peptides (MIPs) are collectively referred to as the immunopeptidome.
From a systems-level perspective, very little is known about the origin, composition and plasticity of
the immunopeptidome. Here, we show that the immunopeptidome, and therefore the nature of
the immune self, is plastic and moulded by cellular metabolic activity. By using a quantitative
high-throughputmassspectrometry-basedapproach,wefoundthatalteringcellularmetabolismviathe
inhibition of the mammalian target of rapamycin results in dynamic changes in the cell surface MIPs
landscape. Moreover, we provide systems-level evidence that the immunopeptidome projects at the cell
surface a representation of biochemical networks and metabolic events regulated at multiple levels
inside the cell. Our ﬁndings open up new perspectives in systems immunology and predictive biology.
Indeed, predicting variations in the immunopeptidome in response to cell-intrinsic and -extrinsic
factors could be relevant to the rational design of immunotherapeutic interventions.
Molecular Systems Biology 7: 533; published online 27 September 2011; doi:10.1038/msb.2011.68
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Introduction
While unicellular eukaryotes primarily employ self/non-self
discrimination to avoid self-mating, multicellular organisms
use self/non-self discrimination primarily in immune defense
(Boehm,2006).Failuretorespondtonon-selfcanleadtodeath
from infection whereas untoward response to self paves the
way to autoimmunity. Peptides presented by major histocom-
patibility complex class I (MHC I) molecules represent the
essenceofselfforCD8Tlymphocytes(Rammenseeetal,1993;
Klein et al, 2009). These MHC I-associated peptides (MIPs)
regulate all key events that occur during the lifetime of CD8
Tcells in the thymus and the periphery (Goldrath and Bevan,
1999; Klein et al, 2009). MIPs are presented at the surface
of most nucleated cells in jawed vertebrates and are
collectively referred to as the MHC I immunopeptidome
(Istrail et al, 2004).
Classic reductionist approaches have established the broad
outlines of the MIP processing system and shown that
MIPs derive from degradation of endogenous proteins by
the proteasome and other peptidases (Yewdell et al, 2003;
Hammer et al, 2007). They have also highlighted the complex-
ity of the MIP repertoire. Thus, MHC I molecules present
peptides encoded not only in the primary open reading frames
but also those encoded in alternate reading frames (Starck and
Shastri, 2011). Moreover, progresses in mass spectrometry
(MS) have allowed increasingly sophisticated and compre-
hensive large-scale analyses of MIPs (Mester et al, 2011).
Large-scale analyses have yielded unprecedented insights into
the peptide speciﬁcities and motifs of MHC molecules and the
diversity of the MIP repertoire (Hunt et al, 1992; Engelhard
et al, 1993; Bonner et al, 2002; Weinzierl et al, 2008). They
havealsodemonstrated that MIPsderivefrom allcellcompart-
ments and that the MIP repertoire can be modiﬁed by
neoplastic transformation (Schirle et al, 2000; Hickman et al,
2004; Weinzierl et al, 2007; Fortier et al, 2008). Nevertheless,
we still know very little about the genesis and molecular
composition of the immunopeptidome: why do proteins such
as STT3B yield abundant MIPs while others do not (Perreault,
2010)? MS studies have also revealed that the immunopepti-
domeisnotarandomsampleoftheproteome:manyabundant
proteins do not generate MIPs, while some low-abundance
proteins generate large amounts of MIPs (Milner et al, 2006).
Furthermore, large-scale analyses have yielded conﬂicting
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repertoire (Weinzierl et al, 2007; Fortier et al, 2008; Mester
et al, 2011). Therefore, further systematic studies based on
high-throughput technologies and integrative approaches are
needed in order to elucidate the mechanisms that mould the
immunopeptidome. In-depth mechanistic understanding of
the immunopeptidome biogenesis would allow prediction of
its molecular composition and would therefore be highly
relevanttothedevelopmentofimmunotherapies(Zarlingetal,
2006; Sette and Rappuoli, 2010).
A key unresolved question is whether the immunopepti-
dome of a particular cell is plastic and affected byits metabolic
state. This issue is of fundamental importance because cells
targeted by CD8 T lymphocytes (i.e. infected and neoplastic
cells) are metabolically perturbed by intracellular parasite/
viruses or various transforming events. We addressed this
question by studying the immunopeptidome of a mouse
lymphoma cell line (EL4) treated with the classic mammalian
target of rapamycin (mTOR) inhibitor, rapamycin. We selected
this model because rapamycin is an exquisitely speciﬁc
inhibitor of the serine/threonine kinase mTOR, and because
mTOR is a central regulator of cellular homeostasis through its
involvement in promoting anabolic and inhibiting catabolic
processes(Senguptaetal,2010).Furthermore,mTORsignaling
is regulated in numerous physiological and pathological
conditions in all cell types, including neoplastic and immune
cells (Araki et al, 2009; Caron et al, 2010; Sengupta et al, 2010).
Results
The effect of rapamycin on mTOR signaling
in EL4 cells
As a prelude to our peptidomic studies, we ﬁrst assessed the
effects of rapamycin on EL4 cells. The ﬁrst mTOR complex,
mTORC1, phosphorylates both S6K1 and 4E-BP1 (Dowling
et al, 2010). Recent studies have shown that rapamycin,
previously thought to completely inhibit mTORC1 activity,
differentially affects 4E-BP1 and S6K1 (Choo et al, 2008; Choo
and Blenis, 2009; Thoreen et al, 2009). While rapamycin
treatmentcompletelyandsustainablyinhibitsS6K1activation,
it partly and variably inhibits 4E-BP1 phosphorylation (Choo
et al, 2008). To evaluate how rapamycin affected mTORC1
signaling in EL4 cells, we treated EL4 cells with rapamycin for
different time durations up to 48h. As expected, Thr-389 on
S6K1 was fully dephosphorylated upon rapamycin treatment,
correlating with a decrease in cell size (Figure 1A and B). In
contrast, Ser-65 and Thr-37/46 on 4E-BP1 were partially
dephosphorylated by rapamycin (Figure 1A). As previously
reported, we also noted that abundance of 4E-BP1 was
decreased after 24h of rapamycin treatment (Figure 1A)
(Dilling et al, 2002). Because 4E-BP1 is critically involved in
cap-dependent translation via regulation of eIF4E, these
results suggested that translation was maintained in EL4 cells
in the presence of rapamycin. Accordingly, we observed that
protein synthesis decreased during the ﬁrst 12h of rapamycin
treatment, but progressively recovered thereafter (Figure 1C).
Prolonged rapamycin treatment for up to 24h has also been
shown to inhibit the assembly of mTORC2, the second mTOR
complex (Sarbassov et al, 2006). Here, we observed that
mTORC2-mediated phosphorylation of AKT at Ser-473 was
transiently decreased but recovered and was increased
after treatment for 48h. Thus, rapamycin treatment for 48h
inhibited mTORC1, but activated mTORC2 in EL4 cells.
Collectively, these results showed that rapamycin-mediated
mTORC1 inhibition perturbed protein synthesis and cell size
by differentially inhibiting S6K1 and 4E-BP1 in EL4 cells
(Figure 1D). Of direct relevance to our analyses of the MIP
landscape, rapamycin treatment did not affect expression
levelsofkeyproteinsinvolvedintheMHCIantigenprocessing
and presentation pathway (Supplementary Figure S1).
High-throughput MS-based studies unveil the
plasticity of the immunopeptidome
The plasticity of the immunopeptidome can only be estimated
by systems-level analyses (Benoist et al, 2006; Germain et al,
2011), and MS with high accuracy analyzers is the most
comprehensive and versatile tool in large-scale proteomics
(Yates et al, 2009). We therefore used a high-throughput MS-
based approach (Fortier et al, 2008; de Verteuil et al, 2010) to
proﬁle in a time-sequential manner the abundance of
MIPs presented by EL4 cells exposed to rapamycin for up to
48h (Figure 2A; Supplementary Information). Subtraction of
‘contaminant peptides’ eluted from b2m mutant EL4 cells
allowed speciﬁc identiﬁcation of genuine MIPs (Supplemen-
tary Table S1) (Fortier et al, 2008; de Verteuil et al, 2010). This
resulted in identiﬁcation and quantiﬁcation of the relative
abundance of 422 unique MIPs associated to different MHC I
allelic products (Figure 2B; Supplementary Table S2). The
salient ﬁnding was that the abundance of most peptides
presented by classical MHC Ia molecules (H2D
b and H2K
b)
increased over time after 12–48h of rapamycin treatment
(Figure 2B). In contrast, the abundance of most peptides
associated to non-classical MHC Ib molecules (Qa1 and Qa2)
was not augmented after treatment with rapamycin for 48h.
Accordingly, exposure to rapamycin led to an increase in cell
surface levels of H2D
b and H2K
b but not Qa1 and Qa2
(Supplementary Figure S2B). Clustering analysis of the time-
seriesdata setsrevealed that theabundance ofnumerousMIPs
increased progressively in response to rapamycin (Supple-
mentary Figure S2A). In general, the dynamic range of this
response was modest with a median fold change in MIP
abundance of 2.1 relative to untreated cells (calculated from
Supplementary Table S2). Nonetheless, a subset of 222 MIPs
showed fold changes between 2 and 15, including 6 MIPs
detected exclusively on rapamycin-treated cells (Supplemen-
tary Table S2). Perturbation of cellular metabolic activity with
rapamycin therefore unveiled the plasticity of the immuno-
peptidome,byincreasingboththeabundanceandthediversity
of MIPs at the cell surface in a time-dependent manner.
mTOR inhibition induces functionally coherent
changes in the transcriptome and the
immunopeptidome
Whether the immunopeptidome accurately projects intracel-
lular metabolic changes to the cell surface is a fundamental
question that has not been addressed yet. More precisely, we
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reﬂected perturbations of rapamycin-sensitive metabolic
processes regulated at the transcript level. To address this
question, we ﬁrst deﬁned the impact of rapamycin on the
transcriptome of EL4 cells. Using NimbleGen MM8 385K
microarrays, we compared the transcriptome of untreated EL4
cellstothatofEL4cellstreatedwithrapamycinfor48h.Atotal
of 1353 differentially expressed transcripts were identiﬁed
(fold change 42.0; Po0.05), which represents about 3% of
transcripts in EL4 cells (Figure 3A). Among these, 903 and 450
mRNAs were under- and overexpressed, respectively. These
genesarehereafterreferredtoasdifferentiallyexpressedgenes
(DEGs). We next compared the 1353 DEGs with 98 unique
source genes coding for the most differentially expressed MIPs
(DEMs) (fold change 42.5; Po0.05: as described in Fortier
et al, 2008) (Figure 3B; Supplementary Table S2). Based on
microarray gene expression data, only two DEM source genes
(Tmod1 and Dhcr7) were found to be differentially expressed
at the transcript level (Figure 3A and B). Interestingly, the only
DEM that was less abundant was also found to be down-
regulated at the transcript level. Thus, these results indicate
that only a minority of DEMs originate from DEGs.
Analysis of Gene Ontology (GO) annotations revealed that
101 and70 genes(Figure 3C; SupplementaryFigureS3B andC)
coding for under- and overexpressed mRNAs were asso-
ciated to 7 and 8 (Figure 3D) signiﬁcantly enriched cellular
processes, respectively (Po0.05) (Supplementary Table S3).
GO term analysis on the 98 DEM source genes also revealed a
signiﬁcant (Po0.05) enrichment for 6 cellular processes
(Figure 3D) implicating 38 DEM source genes (Figure 3C;
Supplementary Figure S3A; Supplementary Table S3). Analy-
sis of DEGs and DEM source genes involved in enriched
cellular processes yielded several ﬁndings. First, there was no
overlap between the 171 DEGs and the 38 DEM source genes
(Figure 3C). Second, cross-comparison of the overrepresented
functional groups identiﬁed four distinct cellular processes
(protein transport, cell cycle/proliferation, DNA replication
and transcription) that were enriched in both DEGs and DEM
source genes (Figure 3D). In order to determine whether this
result implies a signiﬁcant functional relationship between
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oped an all-pairs-shortest-path matrix, which scores the
functional connectivity between two lists of genes
(Figure 4A). Using this matrix, we ﬁrst calculated a con-
nectivity score between the 171 DEGs and the 38 DEM source
genes identiﬁed above. Then, bootstrapping was used as a
statistical sampling method to calculate control connectivity
scores from 10
5 sets of 38 randomly selected MIP source genes
from a database of 891 unique source genes encoding H2
b-
associated peptides (Supplementary Table S4). These analyses
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connected to the 171 DEGs (bootstrapping; P¼0.004)
(Figure4B). Hence,whilemostDEMsdidnotoriginatedirectly
from DEGs, they do originate from genes that are tightly
functionally connected to DEGs. In other words, this systems-
level analysis demonstrates that rapamycin-mediated mTOR
inhibition induces functionally coherent changes in the
transcriptome and the immunopeptidome. Given the tremen-
dous complexity of the transcriptome, this ﬁnding suggests
that the immunopeptidome of the cell is more complex than
anticipated and that its plasticity might be extensive.
DEMs arise from biochemical networks connected
to mTOR
The above results suggested that DEMs originated from genes
connected to the mTOR network. However, considering that
mTOR has a pervasive role in protein synthesis and degrada-
tion (Caron et al, 2010), we could not discard the possibility
that DEMs originated from some non-speciﬁc generic effect
of rapamycin on protein metabolism. In the latter case,
DEM-coding genes would not be tightly connected to the
mTOR network. Hence, in order to further evaluate the
relationship between DEMs and mTOR, we ﬁrst conducted
an analysis on the 98 DEM source genes (Figure 3B;
Supplementary Table S2) using the interaction network
database STITCH (Kuhn et al, 2010). This analysis uncovered
a network containing 30 DEM source genes that were
interconnected and organized within discrete functional
modules (Supplementary Figure S4). Strikingly, the network
included the chemicals rapamycin and everolimus (rapamycin
analog) in addition to components (e.g. Rictor, Sgk1) and
modules (e.g. mTOR signaling, translation, lipid biosynthesis)
known to be directly regulated by mTOR (Caron et al, 2010).
Therefore, we reasoned that rapamycin-mediated changes in
the immunopeptidome might originate from genes that are
very closely connected to components of the mTOR signaling
network. To systematically evaluate this assumption, we
measured the connectivity score between the 30 DEM source
genes and components extracted from a comprehensive map
of the mTOR interactome and signaling network (Supplemen-
tary Table S5 based on Caron et al, 2010). By using the
all-pair-shortest-path matrix described above, we calculated
that the 30 DEM source genes were strongly interconnected
to the mTOR network components relative to random
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 5) (Figure 4C). This
systems-level analysis demonstrates that a substantial fraction
of rapamycin-induced variations in the immunopeptidome
arise from biochemical networks whose components are
highly connected to the target of rapamycin (i.e. mTOR).
Thus,ourdatareinforcethenotionthattheimmunopeptidome
projects a functional representation of intracellular metabolic
changes to the cell surface. Further immunopeptidomic
studies are needed to evaluate whether the mTOR network
regulates the repertoire of MIPs in other contexts.
To visualize the organization of relationships between DEM
source genes, the transcriptome and the mTOR network,
we integrated in a global network the mTOR interactome and
signaling network (Supplementary Table S5 based on Caron
et al, 2010), the 98 DEM source genes (Figure 3B; Supplemen-
tary Table S2) and the 171 DEGs (Figure 3C; Supplementary
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constituents of 7 discrete functional subnetworks (Figure 5A).
All modules included components of the mTOR network.
Integration of microarray data revealed that DEGs were found
in 5 out of the 7 modules containing DEM source genes.
Notably, two modules contained DEM source genes but no
DEGs: the proteasome and the core mTOR signaling modules.
Overall, 82% of the DEM source genes (27/33) were localized
B
B
p
t
f
B
u
b
1
b
C
c
n
f
E
r
b
b
2
i
p
H
i
v
e
p
2
I
g
f
2
r
M
n
a
t
1
M
y
b
P
t
p
n
1
1
T
f
d
p
2
R
c
c
2
R
i
c
t
o
r
S
g
k
1
P
s
m
a
3
P
s
m
b
9
P
s
m
d
2
R
f
c
2
S
u
p
t
1
6
h
T
a
f
6
C
h
t
f
1
8
C
h
a
f
1
b
D
t
l
R
p
l
2
7
R
p
s
1
5
P
a
b
p
c
1
T
n
f
s
f
1
0
N
s
m
a
f
D
h
c
r
7
Total mRNA
NPR
Total mRNA
NPR
Up
Down
No change
Cell cycle/proliferation mTOR 
signaling
Proteasome DNA replication/
transcription
Translation Apoptosis Lipid 
biosynthesis
A
Cell cycle/proliferation
Apoptosis Lipid biosynthesis
mTOR signaling
Translation
Proteasome
DNA replication/
transcription
Up Down
mTOR network component
Other from STITCH
DEM source gene
DEG:
Rapamycin
Sgk1
Rictor
Chtf18
Rfc2
Pcna
Dtl
Rfc1
Pole2
Myc
Gadd45a
Dna2l
Chaf1b
Supt16h
Nf2
Cdc2
Cdk2
Cdkn1b
Cdc45l
Cdc7
Nasp Orc1l
Mcm6
Mcm2
Rpa1
Ccna2
Cdkn2a
Usp7
Mdm2
Rpl11
Ccnb3
Taf7
Taf2
Ppargc1a Thrap3
Taf6
Taf9
Cdk6
Ccnh
Fen1
Rfc1
Mcm7
Ccnb1
Cdkn1a
Sox2
Ruvbl1 Lef1 Frat1
Myb
Bptf
Erbb2ip
Ctnnb1
Pin1
Ptpn11 Igf2r
Ap2a2
Ap2a1
Tfdp2
Mnat1
Ccnf
Bub1b
Cenpm
Rcc2 Bub3
Bub1
Cdc20
Myc
Phb
E2f3
Rara
Gadd45g
Cdkn1a
Sfn
Jak2
Gadd45a
Gsk3b
Ccne2 Cdc2
Cdk2
Rb1
Pcna
Tp53
Akt1
Mapk1 Axin1
Egfr
Erbb3
Mapkap1
Rheb Frap1
Lst8
Raptor
Akt1
Fkbp1a
Eif4e Rps6kb1
Rps6 Eef2k
Bmf
Ihpk2
Casp4
Irak2
Nsmaf
Tnfsf10
Bcl2l11
Kras
Traf2
Card6
Tnfrsf1b
Fas
Ifng
Fadd
Tnfrsf1a
Faslg
Trib3
Ern1
Nr4a1
Casp8
Tradd
Ripk1
Fasn Aacs
Hmgcs1
Mvd
Ldl1
Dhcr24
Hmgcr Ldlr
Nsdhl
Hsd17b7 Dhcr7
Kcnma1
Fabp5
Hnrpab
Ncor1 Ncoa1
Lpin1
Srebf1
Srebf2
Ppar
Ep300
Nrip1
Pcsk9
Apob
Ldlrap1
Apoe
Eef1b
Eef1a2
Rpl10a Rps15a
Eif3b
Eif4a1
Rps13
Rpsa
Pabpc1 Rps27l
Rps15
Eif4ebp2
Eif4ebp1
Eif4g2
Eif4g1
Eif3a
Psma1
Psma7
Psmb9
Psmb1
Psmd2
Psmb7
Psma3
Psmb2 Psmb8
Psmc5 Psmb4
Psmb6 Psma5
Eif4e
Rps3
Eif4a2
Rfc4
Pole
Hivep2
A
p
2
a
1
A
p
2
a
2
C
e
n
p
m
P
i
n
1
Cdk4
P
s
m
b
8
Figure 5 DEM source genes are regulated at multiple layers within speciﬁc mTOR subnetworks. (A) The STITCH database (http://stitch.embl.de/) was used
to generate a network from protein–protein interactions and functional associations involving identiﬁed DEM source genes, DEGs and mTOR network components.
From the total network, subnetworks of DNA replication/transcription, cell cycle/proliferation, apoptosis, lipid biosynthesis, translation, proteasome and mTOR signaling
were extracted. Legend for functional associations (edges) is depicted in Supplementary Figure S4. (B) EL4 cells were treated or not with rapamycin for 48h.
Total mRNA and NPR levels of the DEM source genes depicted in (A) were assessed by quantitative real-time PCR (see also Supplementary Table S6).
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Collectively, these data indicate that rapamycin-induced
variations in the immunopeptidome arise mostly from
transcriptionally perturbed subnetworks that are connected
to components of the mTOR network.
The immunopeptidome integrates events
occurring at the transcriptional and
co- or post-translational level
Generation of MIPs exploits generic cellular processes includ-
ingtranscription,translationand protein degradation (Yewdell
et al, 2003; Fortieret al, 2008;de Verteuilet al,2010). However,
therelativecontributionofthesedifferentregulatoryprocesses
in moulding the immunopeptidome remains elusive. Here, we
ﬁrst sought to determine whether the 33 DEM source genes
depicted in Figure 5A were translationally and/or transcrip-
tionally regulated in response to rapamycin. After 48h
of rapamycin treatment, polysome-associated RNA as well as
total RNA from both rapamycin-treated and -untreated cells
wereanalyzedusing quantitativereal-time PCR. Translation of
a large number of genes is reduced following rapamycin
treatment (Grolleau et al, 2002). Accordingly, analysis
of normalized polysomal mRNAs (NPR) (see Materials and
methods) showed that, in rapamycin-treated cells, ribosomal
loading efﬁciency was decreased for 36% (12/33), and
increased for 6% (2/33) of the DEM source mRNAs
(Figure 5B). In contrast, we observed that 36% (12/33) of
the source genes were upregulated at the transcript level.
Two points can be made from these data. First, while
transcriptional activation could explain the increased abun-
dance of about 36% of MIPs in rapamycin-treated cells,
the role of translational activation appears negligible. As a
corollary, increased levels of 20/33 MIPs can be ascribed to
neither enhanced transcription nor translation of their source
genes. From this, we infer that increased MIP levels on
rapamycin-treated cells are caused mainly by co- and/or post-
translational mechanisms.
In order to probe the role of co- and/or post-translational
mechanisms, we ﬁrst assessed the abundance and stability of
eight DEM source proteins by western blotting on total lysates
from EL4 cells treated or not with rapamycin and cyclohex-
imide (Figure 6; Supplementary Table S6). The abundance of
two proteins was increased (Myb and Tfdp2) while that of the
other six proteins was unchanged (Rfc2, Psmb9, Psmb8,
Pabpc1, Rictor and Sgk1). Notably, the eight DEM source
proteins were relatively stable with a half-life X8h in the
presence or absence of rapamycin. Myb was the only DEM
source protein degraded more rapidly (two-fold; half-life from
8 to 4h) in the presence of rapamycin. These data strongly
suggest that MIP levels do not correlate with the abundance or
stability of the native form of DEM source proteins. However,
upto30%ofproteinsaresorapidlydegraded(withameant1/2
of B10min) by the ubiquitin-proteasome that they escape
detection in standard cycloheximide chase experiments
(Qian et al, 2006). Most of these rapidly degraded proteins
are defective ribosomal products (DRiPs) resulting from
imperfections of protein synthesis or assembly (Yewdell and
Nicchitta, 2006). Accordingly, most protein species have two
half-lives: a longer one for the well-conformed native protein
and a short one for DRiPs. Importantly, MIPs are generated at
higher efﬁciency from rapidlydegraded proteins than from old
proteins (Yewdell et al, 2003; Yewdell and Nicchitta, 2006).
Western blotting experiments on whole EL4 cell extracts
revealed that rapamycin increased the amount of proteasomal
substrates, that is, ubiquitinated proteins that accumulate in
lactacystin-treated cells (Figure 7A). We focused on Rictor, a
DEM source protein that is a component of the mTOR complex
2, to evaluate more speciﬁcally whether rapamycin enhances
proteasomal substrates generation from DEM source proteins.
Rictor is coding for the KALSYASL peptide, which was
exclusively detected after 48h of rapamycin treatment
(Supplementary Table S2). EL4 cells were treated or not with
rapamycin for 48h, with or without lactacystin for the last 8h.
In the presence of lactacystin, we observed a substantial
accumulation of polyubiquitinated Rictor proteins in rapamy-
cin-treated cells relative to untreated cells (Figure 7B). This
result indicates that more polyubiquitinated Rictor proteins
are subjected to proteasome-mediated degradation upon
rapamycin treatment. Because steady-state levels of the native
Rictor protein were not affected by rapamycin (Figure 6), we
infer that the overabundant Rictor MIP derives from a rapidly
degraded pool of Rictor and not from the long-lived native
form of Rictor. Collectively, our data indicate that changes in
the immunopeptidome integrate events occurring at the
transcriptional and co- or post-translational level. Further-
more, consistent with the fact that mTOR links protein quality
and quantity control (Qian et al, 2010), our work suggests that
enhanced generation of rapidly degraded proteasomal sub-
strates is instrumental to rapamycin-induced changes in the
immunopeptidome. Altogether, our results show that the
immunopeptidome projectsat the cell surface a representation
of biochemical networks and metabolic events regulated
at multiple levels inside the cell.
MIPs appearing de novo on rapamycin-treated
cells elicit cytotoxic T-cell responses
Finally, we wished to determine whether MIPs that were
exclusively detected on rapamycin-treated cells could be
antigenic. To test this, we selected the KALSYASL and the
VNTHFSHL peptide, which are encoded by Rictor and Ttc21b,
respectively (Supplementary Table S2). We immunized
C57BL/6 mice with dendritic cells (DCs) coated with
KALSYASL or VNTHFSHL synthetic peptide. Splenocytes from
immunized mice did not kill untreated EL4 cells, but they
showed speciﬁc cytotoxicity for EL4 cells treated with
rapamycin or EL4 cells coated with the peptide used for T-
cell priming (Figure 7C and D; Supplementary Figure S5).
Further studies are needed to evaluate (1) the proportion of
noveloroverabundantMIPsthatareantigenicand(2)whether
particular pathways and cellular processes generate MIPs that
are more likely to be antigenic. Nevertheless, the antigenicity
of KALSYASL and VNTHFSHL is consistent with the notion
that the immune system is tolerant to MIPs expressed
at physiological levels but can mount biologically relevant
immune responses toward self MIPs present in excessive
amounts (Schild et al, 1990).
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Early proteomic studies were conducted with analyzers whose
sensitivity (dynamic range) and accuracy were orders of
magnitude inferior to that of MS analyzers that are now
available(Depontieuetal,2009;Yatesetal,2009;Nilssonetal,
2010). As a result, early studies on the immunopeptidome
identiﬁed only the more abundant MIPs. Those MIPs were
found to derive from highly abundant housekeeping proteins
that are common to many cell types (Marrack et al, 1993;
Hughes and Hughes, 1995; Barnea et al, 2002; Engelhard et al,
2002). More recently, high-throughput MS-based analyses
have shown that the immunopeptidome conceals a cell-type-
speciﬁcsignature.Thus,thoughtheimmunopeptidomeofDCs
and thymocytes partially overlap, no less than 40% of their
MIPs are cell-type speciﬁc (Fortier et al, 2008; de Verteuil et al,
2010). The present study demonstrates that perturbation of a
single signaling pathway can lead to signiﬁcant changes in the
composition of the immunopeptidome. More speciﬁcally,
our work shows that dynamic changes of mTOR signals are
reﬂected in MHC I presentation of numerous peptides
associated with the mTOR interactome and its signaling
network. An important question is whether changes in the
MIP repertoire induced by rapamycin would be found in
response to any type of cell stress. Two elements strongly
support ourcontention that rapamycin-induced changes in the
immunopeptidome are connected to the mTOR network. First,
wefoundthattheconnectivitybetweenDEMsourcegenesand
mTOR network components was amazingly strong (Po10
 5).
A bootstrap procedure (500000 iterations) failed to reveal a
single set of peptide source genes that were so tightly
connected to component of the mTOR network (Figure 4C).
Second, we have previously evaluated the impact of other
types of cell stress (tunicamycin, palmitate or glucose
deprivation) on expression of MHC–peptide complexes at the
surface EL4 cells (the cell line used the present study)
(Granados et al, 2009). We found that cell stress induced
by tunicamycin, palmitate and glucose deprivation led to a
decrease in the generation of MIPs and in the expression of
MHC I molecule. These effects are the exact opposite of what
we found upon treatment of EL4 cells with rapamycin:
overexpression of MHC I molecules (Supplementary Figure
S2B) and increased abundance of cell surface MIPs
(Figure 2B). In our opinion, it is therefore sound to conclude
that rapamycin-induced variations in the immunopeptidome
(1) arise from biochemical networks whose components are
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(2) are not unspeciﬁc changes found with any type of cell
stress. However, mTOR senses and integrates multiple
environmental cues and mTOR network components interact
with many signaling pathways, such as the Wnt pathway
(Inoki et al, 2006; Caron et al, 2010). Therefore, further studies
will be needed to determine whether perturbation of mTOR by
otheragentsorinothercontextswouldbringthesamechanges
in the MIP repertoire as those induced by rapamycin.
An important implication for the immune system is that, at
the peptide level, the immune self is plastic and its molecular
composition is inﬂuenced by the cell’s metabolic activity. We
found that variations in the immunopeptidome functionally
reﬂected perturbations of rapamycin-sensitive metabolic
processes regulated in the transcriptome. More precisely, we
observed that changes in the MIP repertoire originate from
genes that are very closely functionally connected to DEGs.
We observed that only 2% of DEMs did originate directly from
DEGs as measured by DNA microarray experiments. In
contrast, quantitative PCR revealed that 36% of the DEM
source genes were slightly upregulated at the transcript level.
In fact, eight DEM source genes (Bptf, Bub1b, Ccnf, Chaf1b,
Dtl, Mnat1, Myb and Tfdp2) in Figure 3 come from DEGs that
were identiﬁed by quantitative PCR (fold change between 1.2
and 3.1; Supplementary Table S6) but missed by microarrays.
Differences in the sensitivity of both techniques are likely to
explain this discrepancy. Indeed, whereas microarrays permit
genome-wide proﬁling of mRNA expression levels, traditional
quantitative PCR is byfar moresensitive (Germain et al, 2011).
Therefore, genome-wide quantitative PCR would have
revealed a more signiﬁcant overlap between DEM source
genes and DEGs. Although the overlap between DEM source
genes and DEGs was underestimated from microarray data,
altogether our data indicate that changes in MIP abundance
originate mostly from post-transcriptional mechanisms.
Furthermore, data integration analysis revealed that 82% of
DEMs arised from subnetworks that were transcriptionally
reorganized in response to rapamycin. Thus, modulation in
the composition of the immunopeptidome might originate
predominantly from gene-regulatory subnetworks that are
transcriptionally perturbed in response to multiple cellular
stresses (i.e. pathogen infection (Kumar et al, 2010)). In other
words, genes involved in transcriptionally perturbed subnet-
works, although not necessarily differentially expressed at the
transcript level, might participate in modulating the composi-
tion of the immunopeptidome. Consequently, identiﬁcation of
components within transcriptionally perturbed subnetworks
might enable prediction of peptide source genes modulating
the immunopeptidome’s composition.
mTOR integrates environmental cues in terms of nutrients
andgrowthfactors.Therefore,itisreasonabletoinferthatcell-
extrinsic factors modulate the repertoire of self peptides
presented by MHC I. In addition, our results suggest that the
peptide MHC I repertoire is a functional, if not a direct,
representation of the transcriptional state of a cell. Together,
that means the nature of the immune self is much more
complex than anticipated. Moreover, the notion that MIPs
presented speciﬁcally on metabolically stressed cells can be
antigenic (e.g. KALSYASL and VNTHFSHL) could have several
implications that need to be explored: immune responses
against metabolic stress-associated MIPs could contribute to
elimination of infected or transformed cells (Gleimer and
Parham, 2003), but might also elicit autoimmunity (Todd et al,
2008). In keeping with this hypothesis, some self MIPs were
found to be upregulated on infected cells, and some of them
were immunogenic (Herberts et al, 2003; Hickman et al, 2003;
Ovsyannikova et al, 2005).
Fromamoregeneralperspective,ourdataprovide aproofof
concept that acquisition and integration of large-scale,
quantitative biological data from multiple regulatory layers
(i.e. -omics) may enable prediction of variations in the
composition of the immunopeptidome. The notion that the
immunopeptidome is plastic and conveysat the cell surface an
integrative view of cellular protein metabolism opens up new
perspectives in systems immunology and predictive biology
(Benoist et al, 2006; Germain et al, 2011). The immune system
has co-evolved with pathogens and positive selection imposed
bypathogenshashastenedtheevolutionofimmunegenesand
thereby increased the complexity of the immune system
(Waterston et al, 2002; Hedrick, 2004). Given the complexity
of the immune system and the quintessential importance of
self/non-self discrimination, it is imperativeto furtherdevelop
and exploit systems-level quantitative methods that will
enable modeling of the immunopeptidome’s plasticity. Such
systems-oriented approaches will help to simulate and predict
how cell-autonomous and -extrinsic elements modulate the
composition of the immunopeptidome in health and disease.
Materials and methods
Cell culture, ﬂow cytometry and determination
of cell size
EL4cell lineswereculturedaspreviouslyreported(Fortieret al,2008).
Rapamycin, lactacystin and cycloheximide were purchased from
Sigma-Aldrich. For MHC I labeling, cells were stained with anti-
H2D
b (B22–249.R1; Cedarlane), anti-H2K
b (Y3; ATCC), anti-Qa2
(clone 1-1-2; BD Pharmingen), anti-Qa1b (6A8.6F10.1A6) antibodies
and analyzed on a BD LSR II ﬂow cytometer using FACSDiva software
(BD Biosciences) (Meunier et al, 2005). Cell numberand cell size were
measured by light microscopy using an Axio Imager microscope
(Zeiss) and the Northern Eclipse software (Empix Imaging Inc.).
Western blotting and isolation of
polyubiquitinated proteins
EL4 cells were harvested and lysed in RIPA buffer, samples were
resolved by SDS–PAGE and immunoblotted with the following
antibodies: ERAAP (gift from N Shastri, University of California,
Berkeley, CA); Tapasin (gift from TH Hansen, Washington University
School of Medicine, St Louis, MO); Lmp7, Lmp2, b1, b5, ERp57, Sgk1,
b2m, PDI (Abcam); Calnexin, Calreticulin, b-actin (Sigma); PA28,
S6K1, p-S6K1 (Thr-389), 4E-BP1, p-4E-BP1 (Ser-65), p-4E-BP1 (Thr-
37/46),a-tubulin,Rictor,Akt,p-Akt(S473),Ubiquitin(CellSignaling);
Myb (Upstate, Millipore); Mecl1, b2 (Biomol International); Rfc2
(Proteintech Group, PTG); Tfdp2 (Proteintech Group, PTG); Pabpc1
(Cell Signaling); H2K
b/H2D
b (2G5; Thermo Scientiﬁc); Tap1, Tap2
(Santa Cruz Biotechnology). Isolation of polyubiquitinated proteins
was achieved by using Tandem Ubiquitin Binding Entities (TUBEs)
(LifeSensors, Inc.) according to the manufacturer’s instruction.
Metabolic radiolabeling
Tomeasureproteinsynthesis,EL4cellswereculturedintheabsenceor
presence of rapamycin (20ng/ml) for 0h (ctrl), 6, 12, 24 and 48h.
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10
6cells/well, 12 replicates per conditions) and [
3H]-leucine (10mCi/ml)
(Perkin-Elmer) was added to each well. At the end of the culture period,
cells were harvested with a Cell Harvester (Perkin-Elmer) on a ﬁber glass
ﬁlter (Packard) for washing. Filters were dried for 24h and 20mlo f
scintillation liquid per well (MicroScint-O, Perkin-Elmer) was added.
Radioactivity incorporation was determined with the TopCount-NXT
microplate scintillation and luminescence counter (Packard).
Peptide extraction and MS analyses
EL4 cells were treated with 20ng/ml of rapamycin for 0, 6, 12, 24 and
48h. MIPs were then isolated from EL4 cells as described previously
using mild acid elution (Fortier et al, 2008; de Verteuil et al, 2010).
Three biological replicates (5 10
8 EL4 cells per replicate) were
prepared. MIPs obtained after acid elution were separated using an
off-line 1100 series binary LC system (Agilent Technologies) to remove
contaminating species. Peptides were loaded on a homemade strong
cation exchange (SCX) column (0.3mm internal diameter 50mm
length) packed with SCX bulk material (Polysulfoethyl ATM, PolyLC).
Peptides were fractionated with a gradient of 0–25% B after 25min,
25–60% B after 35min (solvent A¼5mmol/l ammonium formate,
15% acetonitrile, pH 3.0; solvent B¼2mol/l ammonium formate,
15% acetonitrile, pH 3.0). MIPs were collected in ﬁve consecutive
fractions and brought to dryness using a speedvac. MIP fractions were
resuspended in 2% aqueous acetonitrile (0.2% formic acid) and
analyzed by nanoLC–MS/MS on a LTQ-Orbitrap mass spectrometer
(Thermo Fisher Scientiﬁc) (Fortier et al, 2008). Full mass spectra were
acquired with the Orbitrap analyzer operated at a resolving power of
60000 (at m/z 400) and collision-activated dissociation tandem mass
spectra were acquired in data-dependent mode with the quadrupole
linear ion trap analyzer. Mass calibration used an internal lock mass
(protonated (Si(CH3)2O))6; m/z 445.12057) and typically provided
mass accuracy within 5p.p.m. for all nanoLC–MS/MS experiments.
MS/MS sequencing, hierarchical clustering and
identiﬁcation of MIP source proteins
Peptidomic data were analyzed using Xcalibur software and peak lists
were generated using Mascot distiller (version 2.1.1, http://www.
matrixscience.com). Database searches were performed against the
International Protein Index mouse database (version 3.23 containing
51536 sequences and 24497860 residues) using Mascot (version 2.2,
http://www.matrixscience.com) with a mass precursor tolerance of
±0.05Da and a fragment tolerance of ±0.5Da. Searches were
performed without enzyme speciﬁcity and a variable modiﬁcation of
oxidized Met. All search results were ﬁltered using an MHC motif ﬁlter
based on the predicted mouse MHC I allele motifs (Supplementary
Information). Raw data ﬁles were converted to peptide maps
comprising m/z values, charge state, retention time and intensity for
all detected ions above a threshold of 10000 counts using in-house
software (Mass Sense) (Fortier et al, 2008; de Verteuil et al, 2010).
Peptide maps were aligned and clustered together to proﬁle the
abundance of Mascot identiﬁed peptides using hierarchical clustering
with criteria based on m/z and time tolerance (±0.02m/z and
±1min). This resulted in a list of non-redundant peptide clusters for
all replicates of all samples to be compared. Peptides found in eluates
from b2m mutant EL4 cells were considered ‘contaminant peptides’.
Subtraction of contaminant peptides eluted from untreated or
rapamycin treated (for 48h) b2m EL4 cells allowed speciﬁc identiﬁca-
tion of genuine MIPs (Fortier et al, 2008; de Verteuil et al, 2010). MIPs
were further inspected for mass accuracy and MS/MS spectra were
validated manually. The Sidekick resource (http://www.bioinfo.
iric.ca/sidekick/Main) was used to identify MIP source proteins. The
list of MIPs reported in the present work has been provided to The
Immune Epitope Database and Analysis Resource (http://beta.immu-
neepitope.org/) (Vita et al, 2010). MS/MS of all peptide identiﬁcations
are available at http://www.thibault.iric.ca/proteoconnections
(Courcelles et al, 2011) under the project name: MHC I immunopepti-
dome,andweresubmittedtothePRIDEdatabase(Vizcaı ´noetal,20 1 0)
under the accession numbers: 18855, 18856.
MIP classiﬁcation and abundance proﬁling
Each MIP listed in Supplementary Tables S1 and S2 was classiﬁed
according to restriction size and binding motif (Fortier et al, 2008; de
Verteuil et al, 2010). The raw ratios for the time proﬁles of detected
MIPs were then clustered using the TIGR MultiExperiment Viewer
(TMEV) software. Hierarchical clustering with Euclidean distances
and average linkage was used.
Microarray analysis
EL4 cells were treated or not with 20ng/ml of rapamycin for 48h.
Three biological replicates were prepared. Total RNA was extracted
from EL4 cells with TRIzol RNA reagent (Invitrogen) as instructed by
the manufacturer. Samples were puriﬁed using DNase (Qiagen) and
the RNeasy Mini kit (Qiagen), and the overall quality was analyzed
with the 2100 Bioanalyzer (Agilent Technologies). Puriﬁed RNA
(10mg/sample) was hybridized on MM8 385K NimbleGen chips
according to the manufacturer’s instruction. Arrays were scanned
using a GenePix4000B scanner (Axon Instruments) at 5mm resolution.
Data were extracted and normalized using the NimbleScan 2.4
extraction software (NimbleGen Systems). Further microarray ana-
lyses were performed using GeneSpring GX 7.3.1. The complete
microarray data sets have been deposited in ArrayExpress (http://
www.ebi.ac.uk/arrayexpress) under accession number E-MEXP-3007.
Isolation of total and polysomal RNA for
quantitative real-time PCR
EL4 cells were treated or not with 20ng/ml of rapamycin for 48h.
Three biological replicates were prepared. Total RNAwas extracted as
described above. Polysomal RNAwas extracted from 2 10
8 EL4 cells
as described previously (Rajasekhar et al, 2003). Gene expression
level was determined using primer and probe sets from Universal
ProbeLibrary (https://www.roche-applied-science.com/sis/rtpcr/
upl/index.jsp). Primer sequences are given in Supplementary Table
S7. PCR reactions for 384-well plate format were performed as
describedinBaronet al(2007). Allreactionswererun intriplicate,and
the mean values were used for quantiﬁcation. The mouse Hprt1 and
Tbp genes were used as endogenous controls for total RNA and
polysomal RNA, respectively. In order to obtain an unbiased proﬁle of
the normalized ribosomal loading efﬁciencies for cells, we calculated
thenetpolysomalmRNAtototalmRNAratios.Suchdataarepresented
in the manuscript as NPR (Rajasekhar et al, 2003).
GO enrichment and connectivity score
The Database for Annotation, Visualization and Integrated Discovery
(DAVID) Bioinformatics Resource (Peters and Sette, 2007) was used to
identify signiﬁcantly enriched GO terms associated to DEM source
genes and DEGs from untreated and rapamycin-treated EL4 cells.
To calculate connectivity scores between two lists of nodes (genes/
proteins), computed scores from STRING (http://string-db.org/)
(Szklarczyk et al, 2011) were used. By using computed scores in
STRING, functional associations between two lists of nodes were
integrated into an all-pairs-shortest-path distance matrix. Each
functional association in the all-pairs-shortest-path matrix was
transformed into a ‘distance’ (D), deﬁned as –ln(S), where S is the
computed STRING score. The all-pairs-shortest-path matrix contains
the length of the shortest path (distance) between every pair of nodes
in the network. A connectivity score was then obtained by calculating
the mean of the shortest path distance between every pair of nodes in
a given matrix.
STITCH network
The 98 DEM source genes highlighted in Figure 3B were used to build
the DEM network (Supplementary Figure S4). The 98 source genes
encoding DEMs, the 171 DEGs classiﬁed within the enriched GO terms
(Po0.05) in Supplementary Figure S3B and C and the mTOR network
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rapamycin-regulatory network. Subnetworks (Figure 5A) were manu-
ally extracted based on the modular organization of the total network
(Hartwell et al, 1999; Rives and Galitski, 2003). Each of these
molecules was individually searched in the STITCH (http://stitch.
embl.de/) (Kuhn et al, 2010) database for its functional associations.
The parameters used to elucidate the network were as follows:
40 additional nodes, a network depth¼1, and interactions with a
minimum STITCH combined score of 0.400. Functional associations
identiﬁed for all of the molecules were then imported into Adobe
Illustrator as a Scalable Vector Graphics image (action view
conﬁguration).
In vitro cytotoxicity assay
Bone marrow-derived DCs were generated as previously described
(Fortieretal,2008;deVerteuiletal,2010).Onday9ofculture,peptides
were added at a concentration of 2 10
 6M and incubated with DCs
for 3h at 371C. For mouse immunization, 10
6 peptide-pulsed DCs
were injected i.v. in C57BL/6 females at day 0 and day 7. On day 14,
splenocytes were harvested from the spleens of immunized mice and
depleted of red blood cells using 0.83% NH4Cl. Cells were plated
at 5 10
6cells/well in 24-well plates and restimulated with 2 10
 6M
peptide at 371C. After 6days, cytotoxicity was evaluated by a 4-h
CFSE-based assay. The percentage of speciﬁc lysis was calculated as
follows: (number of remaining CFSEþ cells after incubation of target
cells alone – number of remaining CFSEþ cells after incubation with
effector cells)/number of CFSEþ cells after incubation of target cells
alone  100.
Supplementary information
Supplementary information is available at the Molecular Systems
Biology website (www.nature.com/msb).
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